Search
Adagene Inc
ADAGAdd to Watchlist
2.980USD
+0.010+0.34%
Close 09-23 16:00（ET）
196.90MMarket Cap
LossP/E TTM
About Adagene Inc Company
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.
Adagene Inc Profile
Ticker SymbolADAG
Company nameAdagene Inc
IPO dateFeb 09, 2021
CEOLuo (Peter)
Number of employees138
Security typeDepository Receipt
Fiscal year-endFeb 09
Address4F, Building C14, No. 218, Xinghu Street
CitySUZHOU
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryChina
Postal code- -
Phone8651287773632
Websitehttps://www.adagene.com/
Ticker SymbolADAG
IPO dateFeb 09, 2021
CEOLuo (Peter)
Company Executives of Adagene Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Peter (Peizhi) Luo, Ph.D.
Dr. Peter (Peizhi) Luo, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
1.64M
+1.23%
Dr. Peter (Peizhi) Luo, Ph.D.
Dr. Peter (Peizhi) Luo, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
1.64M
+1.23%
Dr. Peter (Peizhi) Luo, Ph.D.
Dr. Peter (Peizhi) Luo, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
1.64M
+1.23%
Dr. Fangyong (Felix) Du, Ph.D.
Dr. Fangyong (Felix) Du, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Dr. Xu Jc, M.D., Ph.D.
Dr. Xu Jc, M.D., Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Zhao Qinghai, Ph.D.
Mr. Zhao Qinghai, Ph.D.
Chief Manufacturing Officer
Chief Manufacturing Officer
--
--
Mr. Tam (Raymond) Man Kin
Mr. Tam (Raymond) Man Kin
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Ms. Gu (Vicky) Chunfang
Ms. Gu (Vicky) Chunfang
Senior Director of Finance
Senior Director of Finance
--
--
Ms. Zhou Ling
Ms. Zhou Ling
Senior Director of Human Resources
Senior Director of Human Resources
--
--
Ms. Li Yan
Ms. Li Yan
Senior Vice President of Bioinformatics and Information Technology
Senior Vice President of Bioinformatics and Information Technology
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Peter (Peizhi) Luo, Ph.D.
Dr. Peter (Peizhi) Luo, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
1.64M
+1.23%
Dr. Peter (Peizhi) Luo, Ph.D.
Dr. Peter (Peizhi) Luo, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
1.64M
+1.23%
Dr. Peter (Peizhi) Luo, Ph.D.
Dr. Peter (Peizhi) Luo, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
1.64M
+1.23%
Dr. Fangyong (Felix) Du, Ph.D.
Dr. Fangyong (Felix) Du, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Dr. Xu Jc, M.D., Ph.D.
Dr. Xu Jc, M.D., Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Zhao Qinghai, Ph.D.
Mr. Zhao Qinghai, Ph.D.
Chief Manufacturing Officer
Chief Manufacturing Officer
--
--
FAQs
Who are the top five shareholders of Adagene Inc?
The top five shareholders of Adagene Inc are: Dr. Peter (Peizhi) Luo, Ph.D.
How many institutions hold shares of Adagene Inc (ADAG)?
As of 2026Q1, 38 institutions hold shares of Adagene Inc, with a combined market value of approximately 13.55M, accounting for 20.51% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -2119805.00.